

**Supplementary Table 3** Psoriatic Arthritis MRI Score individual features improvement from baseline to week 24, for the trial population and per treatment group.

| PSAMRIS                    | Baseline (mean) | Week 24 (mean) | P value <sup>a)</sup> Combined | P value <sup>b)</sup> GLM+MTX | P value <sup>c)</sup> PLB/MTX |
|----------------------------|-----------------|----------------|--------------------------------|-------------------------------|-------------------------------|
| <b>MCPs</b>                |                 |                |                                |                               |                               |
| Synovitis                  | 3.61            | 1.21           | <0.001                         | 0.005                         | 0.003                         |
| Flexor tenosynovitis       | 0.51            | 0.39           | 0.229                          | 0.063                         | 0.315                         |
| Periarticular inflammation | 3.06            | 1.00           | <0.001                         | 0.026                         | 0.002                         |
| Bone marrow edema          | 3.81            | 1.11           | <0.001                         | 0.018                         | 0.005                         |
| Bone erosions              | 1.76            | 1.97           | 0.655                          | 0.655                         | 0.655                         |
| Bone proliferation         | 2.13            | 2.17           | NA                             | 1.000                         | 1.000                         |
| <b>PIPs</b>                |                 |                |                                |                               |                               |
| Synovitis                  | 1.44            | 0.67           | <0.05                          | 0.006                         | 1.000                         |
| Flexor tenosynovitis       | 0.51            | 0.39           | 0.229                          | 0.063                         | 0.915                         |
| Periarticular inflammation | 0.33            | 0.40           | 0.317                          | 1.000                         | 0.317                         |
| Bone marrow edema          | 3.86            | 1.86           | 0.050                          | 0.011                         | 0.197                         |
| Bone erosions              | 1.50            | 1.97           | 0.180                          | 1.000                         | 0.144                         |
| Bone proliferation         | 2.67            | 2.54           | NA                             | 1.000                         | 1.000                         |
| <b>DIPs<sup>d)</sup></b>   |                 |                |                                |                               |                               |
| Synovitis                  | 1.00            | 0.36           | 0.059                          | 0.317                         | 0.102                         |
| Flexor tenosynovitis       | 1.14            | 0.73           | 0.099                          | 0.102                         | 0.408                         |
| Periarticular inflammation | 0.54            | 0.25           | 0.046                          | 0.157                         | 0.157                         |
| Bone marrow edema          | 1.73            | 0.86           | 0.102                          | 0.317                         | 0.157                         |
| Bone erosions              | 4.27            | 4.31           | 1.000                          | 1.000                         | 1.000                         |
| Bone proliferation         | 2.08            | 1.58           | 0.317                          | 0.317                         | 1.000                         |

<sup>a)</sup> Differences in PSAMRIS partial scores between baseline and week 24 for combined treatment groups.

<sup>b)</sup> Differences in PSAMRIS partial scores between baseline and week 24 for golimumab plus methotrexate groups.

<sup>c)</sup> Differences in PSAMRIS partial scores between baseline and week 24 for placebo plus methotrexate groups.

<sup>d)</sup> DIP readings applicable only to the hands.

DIP: distal inter-phalangeal joints; GLM: golimumab; MCP/MTP: metacarpal/metatarsophalangeal joints; MRI: magnetic resonance imaging; MTX: methotrexate; PIP: proximal inter-phalangeal joints; PLB: placebo; PSAMRIS: Psoriatic Arthritis MRI Score